Efficient T-cell engineering is crucial for the success of CAR T-cell therapy research, but it requires multiple labor-intensive steps, including T-cell isolation, activation, and transduction.

CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...

Lymph nodes, considered the command centers of our immune system, often get swollen and stiff when fighting infection. Now, a UC Berkeley-led team of researchers has discovered that this mechanical ...

Metabolism guides the activation states of regulatory T cells, the immune cells that prevent inappropriate activation of the immune system. St. Jude Children's Research Hospital scientists recently ...

For decades, cancer immunotherapy has focused primarily on CD8+ cytotoxic T lymphocytes as the main executors of tumor cell ...

Researchers developed a CAR-T manufacturing strategy using the cytokine fusion scaffold HCW9206 to generate longer-lasting ...

Renier Brentjens, MD, PhD, one of the pioneers in the development of chimeric antigen receptor (CAR) T-cell therapy, is poised to see the technology take its next big leap, with researchers testing ...